Nucleic acid-based bioactive substances have recently emerged as a new class of next-generation therapeutics, but their development has been limited by their relatively weak delivery into target cells. Cationic liposomes have been studied as a means to enhance the stability of nucleic acid therapeutics in the bloodstream and improve their cellular delivery. As nucleic acid therapeutics, siRNA and plasmid DNA have been extensively tested for delivery using cationic liposomes. This review discusses recent progress in the application of cationic liposomes for the delivery of nucleic acid therapeutics.
No takes yet. Share an insight, caveat, or question.
Shim et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: